Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VCT 220 (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Corxel Pharmaceuticals

Most Recent Events

29 Jan 2026 New trial record
22 Jan 2026 According to a Corxel Pharmaceuticals media release, the company announced the successful completion of its Series D1 financing, raising up to 287 million dollar in capital. Proceeds from the financing will be used for its planned global Phase 2 trial to treat Type 2 Diabetes Mellitus (T2DM).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com